Lamisil (Terbinafine Hydrochloride)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of the fungal cell membrane. This blockage leads to squalene buildup and ergosterol depletion, compromising membrane integrity and causing fungal cell death.

The specific dosage and duration of Lamisil therapy are determined by the prescribing healthcare professional based on the infection type, severity, patient age, and other clinical factors. Patients should follow the prescriber’s instructions precisely.

Safety data for topical terbinafine during pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits against any possible risks before prescribing Lamisil to pregnant or nursing individuals.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Lamisil belongs to the allylamine class, which differs from azole antifungals that inhibit lanosterol 14α‑demethylase. Allylamines like terbinafine often achieve faster fungal clearance with a lower risk of drug‑enzyme interactions, making them a preferred option for many superficial dermatophyte infections.

Lamisil should be stored at room temperature, below 25 °C, in its original container. Protect the product from moisture, direct sunlight, and extreme temperatures to maintain its stability and effectiveness.

Lamisil is applied topically to the affected skin area, typically once or twice daily as directed by a healthcare professional. The skin should be clean and dry before application, and the medication should be spread in a thin layer covering the lesion and a small margin of surrounding skin.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, extensive skin rash, and potential liver toxicity. Patients should seek immediate medical attention if they experience symptoms like swelling, difficulty breathing, jaundice, or persistent severe skin irritation.

Lamisil should be avoided in individuals with known hypersensitivity to terbinafine or any component of the formulation. It is also contraindicated on severely damaged or broken skin, and caution is advised for patients with pre‑existing liver disease or those taking interacting medications.